Hoth Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Hoth Therapeutics's earnings have been declining at an average annual rate of -6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Anahtar bilgiler
-6.0%
Kazanç büyüme oranı
30.8%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | n/a |
| Özkaynak getirisi | -79.9% |
| Net Marj | n/a |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury
Sep 20Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
Jun 29Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation
Nov 12
Hoth Therapeutics extends agreement for experimental antibiotic
Jun 18We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate
Jun 10Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic
May 05Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers
May 03Hoth provides pipeline and regulatory timeline update
Feb 02FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%
Jan 13Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer
Jan 11Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%
Jan 04Hoth therapeutics signs production agreement for HT-001, Shares up 75%
Dec 31Gelir ve Gider Dağılımı
Hoth Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -7 | 5 | 3 |
| 31 Mar 24 | 0 | -8 | 5 | 3 |
| 31 Dec 23 | 0 | -8 | 4 | 3 |
| 30 Sep 23 | 0 | -10 | 5 | 4 |
| 30 Jun 23 | 0 | -10 | 5 | 5 |
| 31 Mar 23 | 0 | -11 | 6 | 5 |
| 31 Dec 22 | 0 | -11 | 6 | 5 |
| 30 Sep 22 | 0 | -11 | 6 | 5 |
| 30 Jun 22 | 0 | -12 | 5 | 6 |
| 31 Mar 22 | 0 | -13 | 6 | 7 |
| 31 Dec 21 | 0 | -14 | 7 | 8 |
| 30 Sep 21 | 0 | -12 | 6 | 6 |
| 30 Jun 21 | 0 | -10 | 6 | 4 |
| 31 Mar 21 | 0 | -10 | 6 | 4 |
| 31 Dec 20 | 0 | -7 | 4 | 3 |
| 30 Sep 20 | 0 | -10 | 7 | 4 |
| 30 Jun 20 | 0 | -10 | 6 | 4 |
| 31 Mar 20 | 0 | -9 | 5 | 3 |
| 31 Dec 19 | 0 | -8 | 5 | 2 |
| 30 Sep 19 | 0 | -4 | 3 | 1 |
| 30 Jun 19 | 0 | -3 | 2 | 1 |
| 31 Mar 19 | 0 | -3 | 2 | 1 |
| 31 Dec 18 | 0 | -2 | 1 | 1 |
| 30 Sep 18 | 0 | -3 | 2 | 1 |
Kaliteli Kazançlar: HOTH is currently unprofitable.
Büyüyen Kar Marjı: HOTH is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: HOTH is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.
Büyüme Hızlandırma: Unable to compare HOTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: HOTH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: HOTH has a negative Return on Equity (-79.89%), as it is currently unprofitable.